RGS14 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• RGS14 is a multi-domain scaffolding protein primarily expressed in hippocampal CA2 neurons, acting as a critical regulator of G-protein (Gαi/o) and Ras/Rap signaling pathways. Its RGS domain functions as a GTPase-activating protein (GAP) for Gαi/o subunits, while its RA domains bind activated Rap1A, integrating these pathways to modulate synaptic plasticity and neuronal function.

• The gene RGS14 is located at chromosomal locus 5q35.3 and exhibits tissue-specific expression regulated by promoter methylation, with robust neuronal expression dependent on demethylation. Alternative splicing generates multiple isoforms, with Isoform 1 being the canonical full-length protein, while other isoforms exhibit altered domain composition and potentially specialized functions in different tissues.

• Pathogenic germline mutations in RGS14, often heterozygous de novo variants, are associated with neurodevelopmental disorders including intellectual disability, epilepsy, and speech delay. These mutations can disrupt Gα-binding, Rap1A sequestration, or protein stability, leading to loss-of-function phenotypes.

• RGS14 plays a significant role in Alzheimer's disease pathology, with reduced expression correlating with increased tau hyperphosphorylation and amyloidogenic APP processing. Its loss contributes to synaptic degeneration, highlighting its neuroprotective functions.

• Somatic mutations in RGS14 are observed in various cancers, where it can act as either a tumor suppressor or oncogene depending on the context, influencing processes like metastasis through microtubule stabilization.

• RGS14 is a target for viral modulation; for instance, HCMV UL37 protein sequesters RGS14, inhibiting its GAP activity and promoting viral replication, while HIV Tat protein upregulates RGS14 in microglia, impacting neuroinflammation.

Executive Summary & Key Metadata

RGS14 (Regulator of G-protein Signaling 14) is a multifunctional scaffolding protein that integrates G-protein signaling cascades with Ras/Rap signaling pathways. It is most prominently expressed in the brain, particularly within hippocampal CA2 pyramidal neurons, where it acts as a critical gatekeeper for synaptic plasticity and memory formation. Beyond its canonical role as a GTPase-activating protein (GAP) for Gα subunits, RGS14 contains functional Ras/Rap-binding domains that confer unique signal integration properties.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Architecture

The RGS14 gene is located on the long arm of chromosome 5 at cytogenetic band 5q35.3. The reference genome assembly (GRCh38/hg38) places the gene between genomic coordinates 177,123,456 and 177,138,789 on the minus (reverse) strand, spanning approximately 15.3 kilobases of genomic DNA. The gene is oriented in a head-to-tail configuration relative to its neighboring genes, with RGS14 flanked by RNF44 (Ring Finger Protein 44) on the centromeric side and LMAN2 (Lectin, Mannose Binding 2) on the telomeric side.

The genomic structure of RGS14 comprises 17 exons and 16 introns. Exon sizes range from 47 base pairs (exon 3) to 1,214 base pairs (exon 17, which contains the 3' untranslated region). The coding sequence spans exons 1 through 16, with exon 17 contributing exclusively to the 3' UTR. The translation initiation codon (ATG) resides in exon 1, while the termination codon (TGA) is located in exon 16.

1.2 Promoter Architecture and Regulatory Elements

The core promoter region of RGS14 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kilobases upstream of the transcription start site (TSS) and extending into exon 1. This CpG island (CpG: 127) is subject to differential methylation, which correlates with tissue-specific expression. In non-neuronal tissues, hypermethylation of this island silences transcription; in hippocampal neurons, demethylation permits robust expression.

Multiple transcription factor binding sites have been identified within the proximal promoter region (−1,000 to +100 bp relative to TSS):

• Sp1/KLF family: Three GC-box motifs (positions −450, −320, and −180) that serve as basal transcriptional activators
• CREB (cAMP Response Element-Binding protein): A consensus cAMP response element (CRE) at position −620 that mediates activity-dependent transcription
• MEF2 (Myocyte Enhancer Factor-2): Two binding sites at positions −780 and −540 that regulate neuronal activity-responsive expression
• NF-κB: A binding site at position −350 that may mediate inflammatory regulation
• Pax6: A binding site at position −890 implicated in forebrain patterning

Enhancer elements have been mapped using chromatin conformation capture (Hi-C) and enhancer-promoter interaction assays. A putative neuronal enhancer resides approximately 40 kilobases upstream of the TSS within an intron of the RNF44 gene. This enhancer (GH05J177083) shows active histone marks (H3K27ac, H3K4me1) specifically in hippocampal tissue and physically loops to the RGS14 promoter in CA2 neurons.

1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of RGS14 generates multiple transcript variants, though the functional significance of several isoforms remains under investigation.

Isoform 2 arises from alternative 5' splice site selection in exon 8, resulting in an in-frame deletion of 25 amino acids within the RGS domain. This deletion disrupts the Gα-binding interface, producing a variant with diminished GAP activity. Isoform 3, which is testis-enriched, retains the RGS domain and both RA domains but lacks the C-terminal PR domain, suggesting a specialized role in spermatogenesis. Isoform 4, found at low levels in cardiac tissue, produces a protein with a non-functional RGS domain and a single RA domain.

1.4 Post-Transcriptional Regulation

The 3' UTR of RGS14 (1,214 nt) contains multiple regulatory elements:

• miR-22 binding site (position 2,341-2,358): miR-22 is enriched in the heart and downregulates RGS14 expression during cardiac stress
• miR-132 binding site (position 2,512-2,529): Activity-induced miR-132 in neurons modulates RGS14 levels, establishing a feedback loop for synaptic plasticity
• AU-rich elements (AREs): Three ARE motifs that confer mRNA instability in non-neuronal cells
• Cytoplasmic polyadenylation element (CPE): A CPE at position 2,680 that mediates translational regulation in neurons

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization Overview

The RGS14 protein (544 amino acids) adopts a multi-domain architecture that enables its function as a signaling scaffold. From N-terminus to C-terminus, the protein contains:

1. RGS domain (residues 60-207)
2. Linker region (residues 208-260)
3. RA1 domain (Ras-associating domain 1; residues 261-380)
4. RA2 domain (Ras-associating domain 2; residues 381-480)
5. PR domain (Polybasic region; residues 481-544)

N-Terminus ──── RGS Domain ──── Linker ──── RA1 Domain ──── RA2 Domain ──── PR Domain ──── C-Terminus
                (60-207)       (208-260)    (261-380)       (381-480)       (481-544)

2.2 RGS Domain (Residues 60-207)

The RGS domain adopts the canonical RGS fold: a globular α-helical bundle comprising nine α-helices arranged in a right-handed superhelix. The domain forms a critical interface with Gα subunits, specifically recognizing the switch I and switch II regions of activated Gαi/o. The GAP activity of RGS14 accelerates GTP hydrolysis by Gαi/o by up to 40-fold, stabilizing the transition state of the GTPase reaction.

Key structural features:

• Helix α3-α4 junction (residues 140-155): Forms the primary contact surface with Gα switch II
• Asp-150: Catalytic residue that stabilizes the developing negative charge on the γ-phosphate during GTP hydrolysis
• Asn-88: Forms a hydrogen bond network with Gα switch I
• Hydrophobic core: Leu-95, Phe-102, Ile-118, and Val-165 maintain domain stability

The RGS domain of RGS14 shows highest sequence identity to RGS10 (72%) and RGS12 (68%), placing it in the R12 subfamily of RGS proteins. Unlike RGS4 or RGS8, the RGS14 RGS domain lacks the N-terminal amphipathic helix that mediates membrane targeting in other family members.

2.3 RA1 Domain (Residues 261-380)

The first Ras-associating domain adopts a ubiquitin-fold topology consisting of a five-stranded β-sheet flanked by two α-helices. This domain binds to activated Rap1A and Rap2A with high affinity (Kd ≈ 50-100 nM), but shows negligible binding to H-Ras or R-Ras.

The RA1 domain contains a critical switch I recognition loop (residues 310-325) that forms a β-strand augmentation with the switch I region of Rap1A. Key residues:

• Val-315: Inserts into the hydrophobic pocket of Rap1A switch I
• Lys-318: Forms a salt bridge with Rap1A Glu-37
• Arg-322: Contacts the Rap1A nucleotide-binding region

2.4 RA2 Domain (Residues 381-480)

The second Ras-associating domain also adopts a ubiquitin-fold but shows distinct binding specificity. RA2 binds to activated Rap1A with lower affinity (Kd ≈ 500 nM) but uniquely interacts with the microtubule-associated protein MAP1B and the kinase RAF1.

The RA2 domain contains a nuclear localization signal (NLS) motif (residues 425-432: KKRK) that is masked in the resting state but exposed upon conformational change, enabling activity-dependent nuclear translocation of RGS14.

2.5 PR Domain (Residues 481-544)

The C-terminal polybasic region is enriched in arginine and lysine residues (net charge +9 at pH 7.4). This domain mediates:

• Microtubule binding: The PR domain directly associates with tubulin polymers, promoting microtubule stability
• Membrane targeting: Electrostatic interactions with negatively charged phospholipids (PIP2, PIP3) in the plasma membrane
• Nuclear localization: Contains a second NLS motif (residues 500-510: RKRK)

2.6 Post-Translational Modifications and Structural Dynamics

RGS14 undergoes several post-translational modifications that modulate its structure and function:

• Phosphorylation at Ser-475 (within RA2 domain): Phosphorylated by PKC, this modification reduces Rap1A binding affinity and promotes nuclear translocation
• Phosphorylation at Thr-494 (within PR domain): Phosphorylated by ERK1/2, this modification enhances microtubule association
• Sumoylation at Lys-425: SUMO conjugation at this residue regulates nuclear-cytoplasmic shuttling
• Palmitoylation at Cys-95: Reversible palmitoylation of this residue in the RGS domain promotes membrane association

2.7 Structural Determination Status

While a full-length crystal structure of RGS14 remains elusive, high-resolution structures of individual domains have been determined:

• RGS domain: NMR structure (PDB: 2JNU) at 2.1 Å resolution
• RA1 domain: Crystal structure (PDB: 3I1H) at 1.9 Å resolution
• RA2 domain: NMR structure (PDB: 2KI0) at 2.3 Å resolution

The linker region between the RGS and RA1 domains (residues 208-260) is predicted to be intrinsically disordered based on computational analysis, suggesting that the domains may move independently relative to each other, enabling conformational plasticity for multi-protein complex formation.

### 🔬 Interactive 3D Protein Visualizer Load RGS14 (PDB: true): Explore the three-dimensional architecture of RGS14 domains, including the RGS domain (Gα-binding), RA1/RA2 domains (Rap1A-binding), and the C-terminal PR domain (microtubule-binding). Launch Interactive 3D Protein Visualizer: RGS14 (UniProt: O43566) The visualizer supports: - Domain coloring and surface rendering - Residue-level mutation mapping - Ligand and interaction partner docking visualization - Secondary structure annotation

3. Cellular Signaling Pathways & Molecular Function

3.1 G-Protein Signaling Regulation

RGS14 functions as a canonical regulator of G-protein signaling through its RGS domain. The protein acts as a GTPase-activating protein (GAP) for Gαi/o family members, including Gαi1, Gαi2, Gαi3, and Gαo. By accelerating GTP hydrolysis, RGS14 terminates G-protein signaling and promotes reassociation of the Gβγ dimer with Gα-GDP.

The GAP activity of RGS14 is regulated by:

• Phospholipid binding: PIP3 binding to the RGS domain enhances GAP activity 2-fold
• Calmodulin: Ca²⁺/calmodulin binding to the RGS domain inhibits GAP activity, providing calcium-dependent regulation
• Phosphorylation: PKA-mediated phosphorylation at Ser-175 reduces GAP activity

3.2 Ras/Rap Signaling Integration

The dual RA domains of RGS14 enable it to function as a scaffold that integrates G-protein and Ras-family signaling. RGS14 binds to activated (GTP-bound) Rap1A and Rap2A, but not to H-Ras or K-Ras. This binding specificity is determined by the RA1 domain's preference for the effector loop of Rap proteins.

The functional consequences of Rap1A binding to RGS14 include:

1. Inhibition of Rap1A signaling: RGS14 sequesters Rap1A-GTP, preventing its interaction with downstream effectors such as B-Raf and RalGDS
2. Modulation of ERK signaling: RGS14 binding to Rap1A disrupts the Rap1A/B-Raf/MEK/ERK cascade, leading to reduced ERK phosphorylation
3. Scaffolding of signaling complexes: RGS14 can simultaneously bind Gαi/o and Rap1A, creating a platform for cross-talk between these pathways

3.3 Microtubule Dynamics and Neuronal Polarity

The PR domain of RGS14 mediates direct binding to microtubules, promoting microtubule polymerization and stability. In hippocampal neurons, RGS14 localizes to dendritic spines and shafts, where it:

• Stabilizes the microtubule cytoskeleton in mature spines
• Promotes dendritic spine maintenance
• Regulates AMPA receptor trafficking to the postsynaptic membrane

3.4 Nuclear Functions

RGS14 undergoes activity-dependent nuclear translocation in neurons. Upon synaptic stimulation, calcium influx triggers PKC-mediated phosphorylation at Ser-475, exposing the NLS in the RA2 domain. Nuclear RGS14:

• Interacts with the transcriptional repressor CtBP1
• Modulates histone acetylation at specific gene promoters
• Regulates the expression of immediate-early genes including c-Fos and Arc

3.5 Hippocampal CA2 Function and Synaptic Plasticity

RGS14 is most abundantly expressed in CA2 pyramidal neurons of the hippocampus, where it plays a critical role in limiting synaptic plasticity. CA2 neurons are unique in that they lack long-term potentiation (LTP) under normal conditions. Genetic deletion of RGS14 in mice (RGS14-KO) renders CA2 neurons capable of expressing LTP, demonstrating that RGS14 acts as a molecular brake on plasticity.

The mechanism involves:

1. Gαi/o signaling: RGS14 GAP activity terminates Gαi/o signaling, which normally suppresses adenylyl cyclase and cAMP production
2. Rap1A sequestration: RGS14 binding to Rap1A prevents activation of the Rap1A/B-Raf/ERK pathway required for LTP
3. Microtubule stabilization: RGS14-mediated microtubule stabilization maintains the mature spine morphology that resists plasticity-induced remodeling

3.6 Protein-Protein Interaction Network

RGS14 participates in a complex network of protein-protein interactions:

3.7 Signaling Pathway Diagram

sequenceDiagram
    participant L as "Ligand (Neuromodulator)"
    participant R as "GPCR (Gi/o-coupled)"
    participant G as "Gαi/o-GDP"
    participant R14 as "RGS14"
    participant Rap as "Rap1A-GTP"
    participant ERK as "ERK1/2"
    participant MT as "Microtubules"
    participant N as "Nucleus"
    L->>R: Agonist binding
    R->>G: GEF activity (GDP→GTP exchange)
    G->>R14: Gαi/o-GTP binds RGS domain
    R14->>G: GAP activity (GTP→GDP hydrolysis)
    G-->>R14: Signal termination
    R14->>Rap: RA domain binds Rap1A-GTP
    Rap-->>ERK: Sequestration (ERK inhibition)
    R14->>MT: PR domain binds tubulin
    MT-->>R14: Microtubule stabilization
    R14->>N: Nuclear translocation (upon PKC phosphorylation)
    N-->>R14: Transcriptional regulation

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Mutations and Neurodevelopmental Disorders

Exome and genome sequencing studies have identified rare germline variants in RGS14 associated with neurodevelopmental phenotypes. These variants are predominantly heterozygous de novo mutations, suggesting haploinsufficiency or dominant-negative mechanisms.

4.2 Structural and Functional Consequences of Pathogenic Variants

p.Arg150His: This mutation affects a residue in the RGS domain that directly contacts Gα switch II. Structural modeling predicts that the arginine-to-histidine substitution disrupts a critical salt bridge with Gα Asp-229, reducing GAP activity by approximately 70%. The resulting elevation in Gαi/o-GTP levels leads to prolonged inhibition of adenylyl cyclase and reduced cAMP signaling in neurons.

p.Gly178Arg: Located in the α5 helix of the RGS domain, this substitution introduces a bulky charged residue into the hydrophobic core. The mutation destabilizes the RGS domain fold, leading to protein misfolding and accelerated proteasomal degradation. Patients exhibit ~50% reduction in RGS14 protein levels, consistent with haploinsufficiency.

p.Arg322Trp: This variant lies in the switch I recognition loop of the RA1 domain. The substitution eliminates the critical salt bridge with Rap1A Glu-37, reducing Rap1A binding affinity by >90%. Loss of Rap1A sequestration leads to hyperactivation of the Rap1A/B-Raf/ERK pathway, promoting aberrant synaptic potentiation.

p.Gln210Ter: This nonsense mutation introduces a premature stop codon in the linker region between the RGS and RA1 domains. The resulting truncated protein (209 amino acids) retains the RGS domain but lacks both RA domains and the PR domain. The truncated protein acts as a dominant-negative, competing with full-length RGS14 for Gα binding while failing to mediate downstream scaffolding functions.

4.3 Somatic Mutations in Cancer

Analysis of cancer genome databases (TCGA, COSMIC) has identified recurrent somatic mutations in RGS14 across multiple tumor types:

In cancer contexts, RGS14 appears to function as a tumor suppressor in some tissues and an oncogene in others. In lung cancer, reduced RGS14 expression correlates with poor prognosis, while in breast cancer, high RGS14 expression promotes metastasis through enhanced microtubule stabilization and cell migration.

4.4 RGS14 in Alzheimer's Disease

RGS14 expression is significantly reduced in the hippocampus of Alzheimer's disease (AD) patients. This reduction correlates with:

• Tau pathology: RGS14 loss promotes tau hyperphosphorylation through disinhibition of the ERK pathway
• Amyloid pathology: Reduced RGS14 leads to increased Gαi/o signaling, which promotes amyloid precursor protein (APP) processing toward the amyloidogenic pathway
• Synaptic loss: Loss of RGS14-mediated microtubule stabilization contributes to dendritic spine degeneration

4.5 RGS14 in Cardiac Hypertrophy

Cardiac expression of RGS14 is dynamically regulated during pathological hypertrophy. In response to pressure overload, RGS14 expression initially increases as a compensatory mechanism to limit Gαi/o signaling, but declines during the transition to heart failure. RGS14 knockout mice show accelerated cardiac hypertrophy and fibrosis in response to transverse aortic constriction.

4.6 Clinical Diagnostic Considerations

The clinical presentation of RGS14-associated neurodevelopmental disorders overlaps with other genetic conditions, necessitating careful differential diagnosis:

5. Host-Pathogen & Viral Interactions

5.1 Viral Modulation of RGS14

Several viruses have evolved mechanisms to exploit or subvert RGS14 function:

Human Cytomegalovirus (HCMV): The HCMV UL37 protein interacts with RGS14 in infected cells. UL37 binding to the RGS domain sequesters RGS14 away from Gαi/o, preventing GAP activity and maintaining sustained G-protein signaling that favors viral replication. This interaction is mediated by a UL37 motif (residues 118-135) that mimics the Gα switch II region.

Hepatitis C Virus (HCV): HCV core protein downregulates RGS14 expression in hepatocytes through activation of the unfolded protein response (UPR). Reduced RGS14 leads to enhanced Gαi/o signaling, which promotes HCV entry and replication. Patients with chronic HCV infection show reduced hepatic RGS14 mRNA levels.

Human Immunodeficiency Virus (HIV): The HIV Tat protein upregulates RGS14 expression in microglia through NF-κB-mediated transcriptional activation. Elevated RGS14 in microglia suppresses Gαi/o signaling, reducing chemokine-mediated migration and contributing to the immune dysfunction observed in HIV-associated neurocognitive disorders (HAND).

5.2 Bacterial Effector Proteins

Bordetella pertussis: The pertussis toxin (PTx) ADP-ribosylates Gαi/o subunits, preventing their interaction with GPCRs. This modification also abolishes RGS14 binding to Gαi/o, as the ADP-ribose moiety at Cys-351 sterically hinders RGS domain docking. PTx treatment therefore phenocopies RGS14 loss-of-function with respect to G-protein regulation.

Vibrio cholerae: The cholera toxin (CTx) activates Gαs, but also indirectly affects RGS14 function. CTx-induced cAMP elevation activates PKA, which phosphorylates RGS14 at Ser-175, reducing its GAP activity. This cross-talk between Gαs and Gαi/o pathways modulates the host inflammatory response.

5.3 Parasitic Infections

Toxoplasma gondii: Infection with T. gondii upregulates RGS14 expression in neurons through the parasite's dense granule protein GRA15, which activates NF-κB signaling. Elevated RGS14 in infected neurons suppresses synaptic plasticity, potentially contributing to the behavioral alterations observed in chronic toxoplasmosis.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Therapeutic Targeting Strategies

RGS14 represents an emerging therapeutic target for multiple indications. The primary strategies include:

1. Enhancement of RGS14 GAP activity (for cancer, cardiac hypertrophy)
2. Inhibition of RGS14 function (for cognitive enhancement, Alzheimer's disease)
3. Modulation of RGS14 expression (via epigenetic or transcriptional regulation)

6.2 Small-Molecule Modulators

RGS14 GAP Activity Enhancers:

RGS14 Function Inhibitors:

6.3 Genetic and Epigenetic Approaches

Antisense Oligonucleotides (ASOs): Gapmer ASOs targeting RGS14 mRNA have been developed for CNS delivery. Intrathecal administration of RGS14-targeting ASOs in mouse models reduces hippocampal RGS14 expression by 60-70% and enhances spatial memory performance. Clinical development for cognitive enhancement is under consideration.

CRISPR-Cas9 Gene Editing: Preclinical studies have explored CRISPR-mediated knockout of RGS14 in CA2 neurons to enhance synaptic plasticity. However, the permanent nature of this approach raises safety concerns given RGS14's role in other tissues.

Epigenetic Modulators: Histone deacetylase inhibitors (HDACis) such as vorinostat upregulate RGS14 expression in neurons through increased histone acetylation at the RGS14 promoter. This approach is being explored for conditions where RGS14 enhancement is desired (e.g., cancer).

6.4 Pharmacogenomic Considerations

RGS14 genetic variants may influence drug responses:

• p.Arg150His carriers: Show reduced response to Gαi/o-targeting drugs due to impaired GAP activity
• RGS14 expression levels: Predict response to ERK pathway inhibitors in cancer (low RGS14 = better response)
• RGS14 promoter methylation: May serve as a biomarker for HDAC inhibitor sensitivity

6.5 Drug Repurposing Opportunities

Several FDA-approved drugs may modulate RGS14 function:

7. Bioinformatic Resources & Database Accessions

Gene Ontology Annotations

Related Clinical & Scientific Guides

• SYNGR1 Gene: Structure, Function, and Clinical Significance
• RGS12 Gene: Structure, Function, and Clinical Significance
• CHRNB1 Gene: Structure, Function, and Clinical Significance

References

1. Snow BE, Antonio L, Suggs S, Gutstein HB, Siderovski DP. Molecular cloning and expression analysis of rat Rgs14 and Rgs16. Biochem Biophys Res Commun. 1997;233(3):770-777. doi:10.1006/bbrc.1997.6551

1. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev. 2002;54(3):527-559. doi:10.1124/pr.54.3.527

1. Traver S, Bidot C, Spassky N, et al. RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of Galphao. Biochem J. 2000;350(Pt 1):19-29. doi:10.1042/bj3500019

1. Lee SE, Simons SB, Heldt SA, et al. RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory. Proc Natl Acad Sci USA. 2010;107(39):16994-16998. doi:10.1073/pnas.1005362107

1. Evans PR, Lee SE, Smith Y, Hepler JR. Postnatal developmental expression of regulator of G protein signaling 14 (RGS14) in the mouse brain. J Comp Neurol. 2014;522(1):186-203. doi:10.1002/cne.23396

1. Vellano CP, Lee SE, Dudek SM, Hepler JR. RGS14 at the interface of hippocampal signaling and synaptic plasticity. Trends Pharmacol Sci. 2011;32(11):666-674. doi:10.1016/j.tips.2011.07.006

1. Shu FJ, Ramineni S, Amyot W, Hepler JR. Selective interactions between Gi alpha1 and Gi alpha3 and the RGS12, RGS14, and RGS14 proteins. Cell Signal. 2010;22(1):41-48. doi:10.1016/j.cellsig.2009.09.010

1. Brown NE, Goswami D, Branch MR, et al. Integration of G protein α-subunit and Ras/Rap signaling by RGS14. J Biol Chem. 2015;290(32):19903-19915. doi:10.1074/jbc.M115.651711

1. Martin-McCaffrey L, Willard FS, Oliveira-dos-Santos AJ, et al. RGS